Although anti-type II collagen antibodies exhibit some specificity, only 30–60% of RP patients test positive for these antibodies (61).Genetic alterations, such as HLA typing and UBA1 somatic mutations, have been identified in RP patients and may also serve as potential biomarkers (62). Here, UBA1 is linked to retinitis pigmentosa 1.